Press-release for stocks

Prices are updated after-hours

crawled time : 12:01

save search

Arvinas Releases Interim Clinical Data Further Demonstrating the Powerful Potential of PROTAC® Protein Degraders ARV-471 and ARV-110
Published: 2020-12-14 (Crawled : 12:01) - globenewswire.com
ARVN | $34.78 1.43% 1.41% 940K

Health Technology

| 11.73% | O: 129.34% H: 9.27% C: -14.95%
potential

Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design
Published: 2023-05-31 (Crawled : 12:01) - globenewswire.com
ARDS | $0.0615 2.82% 410K

Health Technology

| -67.57% | O: 94.59% H: 49.86% C: 10.39%
ar-301 fda agreement study

Genetic Technologies Provides Update on its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing
Published: 2021-01-21 (Crawled : 12:01) - globenewswire.com
GENE | $2.27 -6.97% -7.49% 64K

Health Technology

| -43.26% | O: 76.74% H: 7.63% C: -27.89%
covid test disease risk expansion

VERU-111, Cytoskeleton Disruptor, Demonstrates Efficacy in Preclinical Models of Human Triple Negative Breast Cancer
Published: 2020-12-14 (Crawled : 12:01) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M

Health Technology

| -77.66% | O: 55.31% H: 9.73% C: -1.77%
breast cancer cancer preclinical pre-clinical

VistaGen Therapeutics Announces Pricing of Underwritten Public Offering
Published: 2020-12-18 (Crawled : 12:01) - globenewswire.com
VTGN | $4.77 1.49% 1.47% 150K

Health Technology

| 407.72% | O: 24.23% H: 28.7% C: 18.26%
offering therapeutics publication

Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome
Published: 2020-12-15 (Crawled : 12:01) - globenewswire.com
AVXL | News | $3.8 0.0% 2.1M

Health Technology

| -26.78% | O: 20.42% H: 2.08% C: -4.16%
life science trial phase 2 anavex®2-73 anavex syndros rett syndrome

Kaival Brands Acquires Extensive Vaporizer and Inhalation Patent Portfolio to Diversify Product Offerings and Create New Revenue Opportunities
Published: 2023-05-31 (Crawled : 12:01) - globenewswire.com
KAVL | $3.75 8.38% 7.73% 710K

Wholesale Trade

| 507.25% | O: 19.66% H: 1.49% C: -16.4%
patent brands

INmune Bio, Inc. Announces XPro1595 Found to Decrease Neuroinflammation and Neurodegeneration Biomarkers in Patients with Alzheimer’s Disease in Phase 1b Trial
Published: 2021-01-21 (Crawled : 12:01) - globenewswire.com
INMB | $8.33 -5.34% -5.64% 69K

Health Technology

| -66.44% | O: 14.65% H: 4.13% C: -29.31%
disease alzheimer trial phase 1b phase 2b alzheimer’s alzheimer's disease alzheimer's biomarkers

Chimerix Announces FDA Acceptance of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox
Published: 2020-12-07 (Crawled : 12:01) - globenewswire.com
CMRX | $0.8844 -5.14% -5.42% 430K

Health Technology

| -74.31% | O: 11.6% H: 13.37% C: 12.38%
fda drug smallpox fda acceptance new drug application

HEXO Corp announces results of its annual and special meeting of shareholders
Published: 2020-12-14 (Crawled : 12:01) - globenewswire.com
HEXO | $0.71 -0.14% 310K

Process Industries

| -82.25% | O: 10.0% H: 0.0% C: -8.18%
results

Tonix Pharmaceuticals Licenses Technology for Treating Prader-Willi Syndrome, a Rare Genetic Eating Disorder, from the French National Institute of Health and Medical Research (Inserm)
Published: 2021-02-11 (Crawled : 12:01) - globenewswire.com
TNXP | $0.159 1.27% 1.26% 1.1M

Health Technology

| -90.18% | O: 9.2% H: 19.1% C: 12.36%
genetic license research syndros rare

Lee Enterprises posts strong quarter and fiscal year results
Published: 2020-12-10 (Crawled : 12:01) - globenewswire.com
LEE | $12.81 -2.15% 2.1K

Consumer Services

| 10.43% | O: 8.62% H: 0.79% C: -17.46%
results

Futu Announces Agreement to Purchase Shares by a Leading Global Investment Firm
Published: 2020-12-08 (Crawled : 12:01) - globenewswire.com
FUTU | $54.76 -0.16% -0.16% 680K

Technology Services

| 28.47% | O: 8.55% H: 2.32% C: -4.98%

Orchard Therapeutics Announces $150 Million Strategic Financing
Published: 2021-02-05 (Crawled : 12:01) - globenewswire.com
ORTX | $16.7 0.0% 370K

Health Technology

| 167.36% | O: 8.52% H: 15.11% C: 9.48%
therapeutics

Iterum Therapeutics Announces Collaboration with EVERSANA to Support Oral Sulopenem Launch
Published: 2021-02-01 (Crawled : 12:01) - globenewswire.com
ITRM | $1.43 -0.69% 60K

Health Technology

| 1.42% | O: 8.51% H: 4.58% C: 1.31%
collaboration announces collaboration sulopenem

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2021-02-02 (Crawled : 12:01) - globenewswire.com
BCRX | $4.44 -1.33% -1.35% 4.7M

Health Technology

| -62.03% | O: 7.93% H: 0.86% C: -17.67%
granted grant

Avenue Therapeutics Provides Regulatory Update for IV Tramadol
Published: 2020-12-17 (Crawled : 12:01) - globenewswire.com
ATXI | $0.1295 -3.79% -3.94% 320K

Health Technology

| -96.48% | O: 6.23% H: 59.44% C: 39.03%
therapeutics

Reed’s, Inc. Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Financial Results
Published: 2021-01-13 (Crawled : 12:01) - globenewswire.com
REED | $3.24 0

Consumer Non-Durables

| 323.53% | O: 5.88% H: 1.16% C: -4.06%
results